Armin Khosravi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Armin Khosravi has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Ali Salehi
Department of Oral and Maxillofacial Radiology, School of Dentistry, Islamic Azad University, Isfahan (Khorasgan) Branch, Isfahan, Iran
1 shared publication - Elnaz Mousavi
Department of Endodontics, School of Dentistry, Guilan University of Medical Sciences, Rasht, Iran
1 shared publication - Farnoosh Ebrahimzadeh
Department of Internal Medicine, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
1 shared publication - Mohammad Saeed Kahrizi
Department of Surgery, Alborz University of Medical Sciences, Karaj, Iran
1 shared publication - Navid Nasrabadi
Department of Endodontics, School of Dentistry, Birjand University of Medical Sciences, Birjand, Iran
1 shared publication - Samira Jamali
Department of Endodontics, Stomatological Hospital, College of Stomatology, Xi’an Jiaotong University, Shaanxi, People’s Republic of China
1 shared publication
Latest Publications
- Open Access
- 7 June 2023
- Published by Springer Nature in Stem Cell Research & Therapy
- Vol. 14 (1) , 1-18
Recent advances in pre-conditioned mesenchymal stem/stromal cell (MSCs) therapy in organ failure; a comprehensive review of preclinical studies
Mesenchymal stem/stromal cells (MSCs)‐based therapy brings the reassuring capability to regenerative medicine through their self‐renewal and multilineage potency. Also, they secret a diversity of mediators, which are complicated in moderation of deregulated immune responses, and yielding angiogenesis in vivo. Nonetheless, MSCs may lose biological performance after procurement and prolonged expansion in vitro. Also, following transplantation and migration to target tissue, they encounter a harsh milieu accompanied by death signals because of the lack of proper tensegrity structure between the cells and matrix. Accordingly, pre-conditioning of MSCs is strongly suggested to upgrade their performances in vivo, leading to more favored transplantation efficacy in regenerative medicine. Indeed, MSCs ex vivo pre-conditioning by hypoxia, inflammatory stimulus, or other factors/conditions may stimulate their survival, proliferation, migration, exosome secretion, and pro-angiogenic and anti-inflammatory characteristics in vivo. In this review, we deliver an overview of the pre-conditioning methods that are considered a strategy for improving the therapeutic efficacy of MSCs in organ failures, in particular, renal, heart, lung, and liver.
- 7 June 2023
- Published by Springer Nature in Stem Cell Research & Therapy
- Vol. 14 (1) , 1-18
Open AccessRecent advances in pre-conditioned mesenchymal stem/stromal cell (MSCs) therapy in organ failure; a comprehensive review of preclinical studies
Mesenchymal stem/stromal cells (MSCs)‐based therapy brings the reassuring capability to regenerative medicine through their self‐renewal and multilineage potency. Also, they secret a diversity of mediators, which are complicated in moderation of deregulated immune responses, and yielding angiogenesis in vivo. Nonetheless, MSCs may lose biological performance after procurement and prolonged expansion in vitro. Also, following transplantation and migration to target tissue, they encounter a harsh milieu accompanied by death signals because of the lack of proper tensegrity structure between the cells and matrix. Accordingly, pre-conditioning of MSCs is strongly suggested to upgrade their performances in vivo, leading to more favored transplantation efficacy in regenerative medicine. Indeed, MSCs ex vivo pre-conditioning by hypoxia, inflammatory stimulus, or other factors/conditions may stimulate their survival, proliferation, migration, exosome secretion, and pro-angiogenic and anti-inflammatory characteristics in vivo. In this review, we deliver an overview of the pre-conditioning methods that are considered a strategy for improving the therapeutic efficacy of MSCs in organ failures, in particular, renal, heart, lung, and liver.